Merck Nears $6 Billion Acquisition of Terns Pharma to Expand Cancer Portfolio Pharmaceutical company Merck is nearing a roughly $6 billion all-cash deal to acquire biotech firm Terns Pharma, according to reports. The potential acquisition is part of Merck’s strategy to strengthen its oncology division, which focuses on cancer treatments. The company is actively building a dedicated cancer division centered around its blockbuster drug Keytruda, which is expected to face patent expiration in 2028. This move aims to secure its position in the market as competition in oncology therapies intensifies. The deal, which is said to be in advanced stages of negotiations, could see a final agreement within the next few days. Terns Pharma, which specializes in developing treatments for chronic myeloid leukemia, has seen its shares rise by approximately 10% in after-hours trading following the news. However, Merck and Terns Pharma have not yet commented on the potential acquisition, leaving details about the terms and timeline of the deal undisclosed. Merck’s focus on oncology reflects broader industry trends as pharmaceutical companies seek to diversify their portfolios and address unmet medical needs. Keytruda, a PD-1 inhibitor, has been a major revenue driver for Merck, but its patent expiration in 2028 could threaten its long-term profitability. By acquiring Terns Pharma, Merck may gain access to innovative therapies and expand its pipeline of cancer treatments, potentially offsetting the loss of Keytruda’s exclusivity. The acquisition also highlights the growing importance of partnerships and mergers in the pharmaceutical sector. As drug development costs rise and regulatory hurdles increase, companies are increasingly turning to acquisitions to accelerate innovation and reduce financial risks.#merck #keytruda #terns_pharma #chronic_myeloid_leukemia #pd_1_inhibitor
